These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 38003240)

  • 21. HCV core inhibits hepatocellular carcinoma cell replicative senescence through downregulating microRNA-138 expression.
    Shiu TY; Shih YL; Feng AC; Lin HH; Huang SM; Huang TY; Hsieh CB; Chang WK; Hsieh TY
    J Mol Med (Berl); 2017 Jun; 95(6):629-639. PubMed ID: 28258280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of viral protein interaction networks in Hepatitis B virus and Hepatitis C virus infected HCC.
    Yuan W; Huang T; Yu J; Zeng L; Lian B; He Q; Li Y; Zhang X; Zhou F; Xie L
    Biochim Biophys Acta; 2014 Jan; 1844(1 Pt B):271-9. PubMed ID: 23774196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.
    Yamaguchi T; Yoshida K; Murata M; Matsuzaki K
    World J Gastroenterol; 2014 Sep; 20(35):12381-90. PubMed ID: 25253939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures.
    Perez S; Lavi-Itzkovitz A; Gidoni M; Domovitz T; Dabour R; Khurana I; Davidovich A; Tobar A; Livoff A; Solomonov E; Maman Y; El-Osta A; Tsai Y; Yu ML; Stemmer SM; Haviv I; Yaari G; Gal-Tanamy M
    Cell Mol Gastroenterol Hepatol; 2023; 16(1):63-81. PubMed ID: 36965814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of epigenetic aberrations in the development of hepatocellular carcinoma.
    Zhang Y
    Methods Mol Biol; 2015; 1238():709-31. PubMed ID: 25421688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
    Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.
    Quan H; Zhou F; Nie D; Chen Q; Cai X; Shan X; Zhou Z; Chen K; Huang A; Li S; Tang N
    Oncogene; 2014 May; 33(22):2826-35. PubMed ID: 23770846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of TAF1, SAT1, and ARHGEF9 as DNA methylation biomarkers for hepatocellular carcinoma.
    Cai C; Xie X; Zhou J; Fang X; Wang F; Wang M
    J Cell Physiol; 2020 Jan; 235(1):611-618. PubMed ID: 31283007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes.
    Iqbal J; McRae S; Banaudha K; Mai T; Waris G
    J Biol Chem; 2013 Dec; 288(52):36994-7009. PubMed ID: 24240095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
    Virzì A; Roca Suarez AA; Baumert TF; Lupberger J
    Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31501266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma.
    De Giorgi V; Monaco A; Worchech A; Tornesello M; Izzo F; Buonaguro L; Marincola FM; Wang E; Buonaguro FM
    J Transl Med; 2009 Oct; 7():85. PubMed ID: 19821982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets.
    Wijetunga NA; Pascual M; Tozour J; Delahaye F; Alani M; Adeyeye M; Wolkoff AW; Verma A; Greally JM
    Oncogene; 2017 Apr; 36(14):2030-2044. PubMed ID: 27721404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.
    Kanda T; Goto T; Hirotsu Y; Moriyama M; Omata M
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30889843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients.
    El-Araby RE; Khalifa MA; Zoheiry MM; Zahran MY; Rady MI; Ibrahim RA; El-Talkawy MD; Essawy FM
    Cancer Gene Ther; 2020 Jun; 27(6):486-497. PubMed ID: 31316135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients.
    Pontisso P; Belluco C; Bertorelle R; De Moliner L; Chieco-Bianchi L; Nitti D; Lise M; Alberti A
    Cancer; 1998 Oct; 83(8):1489-94. PubMed ID: 9781942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis.
    Dang S; Zhou J; Chen Y; Chen P; Ji M; Shi B; Yang Q; Hou P
    Oncogene; 2019 Jun; 38(24):4804-4819. PubMed ID: 30804458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Differential Immunohistochemical Expression of p53, c-Jun, c-Myc, and p21 Between HCV-related Hepatocellular Carcinoma With and Without Cirrhosis.
    Abdou AG; Abd-Elwahed M; Badr M; Helmy M; Soliman EA; Maher D
    Appl Immunohistochem Mol Morphol; 2016 Feb; 24(2):75-87. PubMed ID: 25710583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma.
    Tsuchiya M; Parker JS; Kono H; Matsuda M; Fujii H; Rusyn I
    Mol Cancer; 2010 Apr; 9():74. PubMed ID: 20380719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma.
    Zheng Y; Hlady RA; Joyce BT; Robertson KD; He C; Nannini DR; Kibbe WA; Achenbach CJ; Murphy RL; Roberts LR; Hou L
    Clin Epigenetics; 2019 Oct; 11(1):145. PubMed ID: 31639042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.